Overview

An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks

Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
A study in patients with atherosclerosis to assess safety, effect and PK of rilapladib vs. placebo over 12 weeks of dosing.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline